Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
- PMID: 21140147
- PMCID: PMC3400085
- DOI: 10.1007/s00280-010-1536-1
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
Abstract
Purpose: To evaluate the maximum tolerated dose (MTD), safety, and antitumor activity of sunitinib combined with paclitaxel and carboplatin.
Methods: Successive cohorts of patients with advanced solid tumors received oral sunitinib (25, 37.5, or 50 mg) for 2 consecutive weeks of a 3-week cycle (Schedule 2/1) or as a continuous daily dose for 3-week cycles (CDD schedule) in combination with paclitaxel (175-200 mg/m(2)) plus carboplatin (AUC 6 mg min/ml) on day one of each of 4 cycles. Dose-limiting toxicities (DLTs) and adverse events (AEs) were evaluated to determine the MTD. Efficacy parameters were analyzed in patients with measurable disease.
Results: Forty-three patients were enrolled (n = 25 Schedule 2/1; n = 18 CDD schedule). Across all doses, 6 DLTs were observed [grade 4 papilledema, grade 5 GI hemorrhage, grade 3 neutropenic infection, and grade 4 thrombocytopenia (n = 3)]. The MTD for Schedule 2/1 was sunitinib 25 mg plus paclitaxel 175 mg/m(2) and carboplatin AUC 6 mg min/ml. The MTD was not determined for the CDD schedule. Treatment-related AEs included neutropenia (77%), thrombocytopenia (56%), and fatigue (47%). Of 38 evaluable patients, 4 (11%) had partial responses and 12 (32%) had stable disease. PK data indicated an increase in maximum and total plasma exposures to sunitinib and its active metabolite when given with paclitaxel and carboplatin compared with sunitinib monotherapy.
Conclusions: Myelosuppression resulting in prolonged dose delays and frequent interruptions was observed, suggesting that this treatment combination is not feasible in the general cancer population.
Similar articles
-
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Invest New Drugs. 2013 Dec;31(6):1487-98. doi: 10.1007/s10637-013-0010-4. Epub 2013 Aug 22. Invest New Drugs. 2013. PMID: 23963796 Free PMC article. Clinical Trial.
-
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.Cancer Chemother Pharmacol. 2012 Jul;70(1):65-74. doi: 10.1007/s00280-012-1880-4. Epub 2012 May 24. Cancer Chemother Pharmacol. 2012. PMID: 22623210 Free PMC article. Clinical Trial.
-
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.Cancer Chemother Pharmacol. 2010 Sep;66(4):669-80. doi: 10.1007/s00280-009-1209-0. Epub 2009 Dec 31. Cancer Chemother Pharmacol. 2010. PMID: 20043166 Free PMC article. Clinical Trial.
-
A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.Cancer Chemother Pharmacol. 2012 Mar;69(3):709-22. doi: 10.1007/s00280-011-1755-0. Epub 2011 Oct 12. Cancer Chemother Pharmacol. 2012. PMID: 21989766 Free PMC article. Clinical Trial.
-
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.NPJ Precis Oncol. 2023 Apr 18;7(1):37. doi: 10.1038/s41698-023-00369-w. NPJ Precis Oncol. 2023. PMID: 37072571 Free PMC article. Review.
Cited by
-
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.Br J Cancer. 2010 Jun 8;102(12):1699-706. doi: 10.1038/sj.bjc.6605696. Epub 2010 May 18. Br J Cancer. 2010. PMID: 20485286 Free PMC article. Clinical Trial.
-
A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs.Front Pharmacol. 2021 Aug 30;12:670862. doi: 10.3389/fphar.2021.670862. eCollection 2021. Front Pharmacol. 2021. PMID: 34526892 Free PMC article. Review.
-
Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group.Br J Cancer. 2012 Feb 14;106(4):629-32. doi: 10.1038/bjc.2011.608. Epub 2012 Jan 12. Br J Cancer. 2012. PMID: 22240783 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Clin Pharmacokinet. 2011 Sep;50(9):551-603. doi: 10.2165/11593320-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21827214
-
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.Br J Cancer. 2013 Apr 16;108(7):1393-401. doi: 10.1038/bjc.2013.96. Epub 2013 Mar 19. Br J Cancer. 2013. PMID: 23511559 Free PMC article. Clinical Trial.
References
-
- National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: NSCLC v.2.2009. 2009 Available via http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
-
- Khosravi SP, Fernandez P,I. Tumoral angiogenesis: review of the literature. Cancer Invest. 2008;26:104–108. - PubMed
-
- Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004;15:205–213. - PubMed
-
- Saltz LB, Clarke S, az-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;20:2013–2019. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources